Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Sarcoma, Ewing 1Rhabdomyosarcoma 1Osteosarcoma 1Neuroblastoma 1Liposarcoma 1

Interventions

Specimen Handling 4Magnetic Resonance Spectroscopy 4Doxorubicin 4pembrolizumab 3Radiotherapy 3Radiation 3Biopsy 3pazopanib 2palbociclib 2abemaciclib 2Immunoglobulin G 2Ifosfamide 2toripalimab 1talimogene laherparepvec 1silmitasertib 1selinexor 1ribociclib 1peposertib 1mirdametinib 1liposomal doxorubicin 1eribulin 1durvalumab 1cemiplimab 1X-Rays 1Vincristine 1Temozolomide 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Proton Therapy 1Neoadjuvant Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Liposarcoma × silmitasertib × 90 days × Clear all
NCT06541262 2026-04-09

Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors

Milton S. Hershey Medical Center

Phase 1/2 Recruiting
104 enrolled
CNSSarcoma

Liposarcoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡